Additional file 1: Figure S1. of Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

Abstract

Viability in UCCs after sequential treatment with AZD7762 and gemcitabine. Relative cell viability in several UCCs was measured by MTT assay (mean ± SD, n = 4) after cells were sequentially treated (pretreated with AZD7762 for 24 h and then incubated with gemcitabine for 48 h). (TIF 142 kb